The National Cancer Institute is funding a Phase 2/3 U.S. trial testing ivonescimab plus chemotherapy versus standard chemoimmunotherapy in advanced biliary tract cancer. The study adds a new checkpoint-targeting and immune-activation strategy to a disease area where patients often receive combination regimens with limited durability, and where predictive biomarkers for response and toxicity remain an ongoing unmet need. For biotech, this matters because NCI-sponsored designs can accelerate recruitment, generate high-quality comparator data, and clarify where the antibody mechanism fits within established treatment lines and escalation strategies.